AR037253A1 - Forma polimorfa de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen - Google Patents

Forma polimorfa de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen

Info

Publication number
AR037253A1
AR037253A1 ARP020104228A ARP020104228A AR037253A1 AR 037253 A1 AR037253 A1 AR 037253A1 AR P020104228 A ARP020104228 A AR P020104228A AR P020104228 A ARP020104228 A AR P020104228A AR 037253 A1 AR037253 A1 AR 037253A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
compositions containing
rimonabant
polymorm
preparation procedure
Prior art date
Application number
ARP020104228A
Other languages
English (en)
Inventor
Alain Alcade
Gilles Anne-Archard
Corinne Gavory
Olivier Monnier
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR037253A1 publication Critical patent/AR037253A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un nuevo polimorfo cristalino de rimonabant, modo de preparación y composiciones farmacéuticas que contienen ese nuevo polimorfo, cuyo espectro de absorción infrarrojo está representado en la figura. Son antagonistas de receptores cannabinoides CB1.
ARP020104228A 2001-11-08 2002-11-06 Forma polimorfa de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen AR037253A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0114579A FR2831883B1 (fr) 2001-11-08 2001-11-08 Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Publications (1)

Publication Number Publication Date
AR037253A1 true AR037253A1 (es) 2004-11-03

Family

ID=8869285

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104228A AR037253A1 (es) 2001-11-08 2002-11-06 Forma polimorfa de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen

Country Status (33)

Country Link
US (2) US20050043356A1 (es)
EP (1) EP1446384A1 (es)
JP (2) JP4181994B2 (es)
KR (2) KR20090089485A (es)
CN (1) CN100412063C (es)
AP (1) AP1830A (es)
AR (1) AR037253A1 (es)
AU (1) AU2002350869B2 (es)
BR (1) BR0213931A (es)
CA (1) CA2464145A1 (es)
CO (1) CO5580827A2 (es)
CR (1) CR7333A (es)
EA (1) EA006771B1 (es)
EC (1) ECSP045088A (es)
FR (1) FR2831883B1 (es)
GE (1) GEP20063894B (es)
HR (1) HRP20040403A2 (es)
HU (1) HUP0402043A3 (es)
IL (2) IL161533A0 (es)
IS (1) IS7226A (es)
MA (1) MA27080A1 (es)
ME (1) MEP21908A (es)
MX (1) MXPA04004394A (es)
NO (1) NO326648B1 (es)
NZ (1) NZ532369A (es)
OA (1) OA12721A (es)
PL (1) PL369372A1 (es)
RS (1) RS36904A (es)
TN (1) TNSN04079A1 (es)
TW (1) TW200302824A (es)
UA (1) UA76776C2 (es)
WO (1) WO2003040105A1 (es)
ZA (1) ZA200402999B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
US6932971B2 (en) 2002-07-18 2005-08-23 Cytos Biotechnology Ag Hapten-carrier conjugates and uses thereof
FR2861992B1 (fr) * 2003-11-10 2007-07-20 Sanofi Synthelabo Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide.
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
EP1816125A1 (en) * 2006-02-02 2007-08-08 Ranbaxy Laboratories, Ltd. Novel crystalline forms of an antagonist of CB1 cannabinoid receptor and preparation method thereof
FR2897060B1 (fr) * 2006-02-08 2008-07-25 Sanofi Aventis Sa Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
WO2008038143A2 (en) * 2006-06-22 2008-04-03 Medichem, S.A. Novel solid forms of rimonabant and synthetic processes for their preparation
WO2008044153A2 (en) * 2006-08-29 2008-04-17 Medichem, S.A. Improved method for synthesizing rimonabant
US20100076022A1 (en) * 2006-09-01 2010-03-25 Hetero Drugs Limited Novel polymorphs of rimonabant
EP2061783A2 (en) * 2006-09-11 2009-05-27 Hetero Drugs Limited Improved process for rimonabant
WO2008035023A1 (en) * 2006-09-19 2008-03-27 Cipla Limited Polymorphs of rimonabant
WO2008056377A2 (en) * 2006-11-06 2008-05-15 Cadila Healthcare Limited Polymorphic forms of rimonabant
WO2008064615A2 (en) * 2006-12-01 2008-06-05 Zentiva, A.S. Crystalline and amorphous forms of rimonabant and processes for obtaining them
JP5437812B2 (ja) * 2006-12-18 2014-03-12 ７ティーエム ファーマ エイ／エス Ｃｂ１受容体モジュレーター
WO2008081208A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
CL2008000017A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
BRPI0806498A2 (pt) 2007-01-04 2014-04-22 Prosidion Ltd Agonistas gpcr piperidina
PE20081659A1 (es) 2007-01-04 2008-10-24 Prosidion Ltd Agonistas de gpcr
EP1944297A1 (en) * 2007-01-09 2008-07-16 Miklós Vértessy Solid and crystalline rimonabant and processes for preparation, and pharmaceutical composition thereof
WO2008088900A2 (en) * 2007-01-18 2008-07-24 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rimonabant base and processes for preparation thereof
EP1953144A1 (en) * 2007-01-30 2008-08-06 Sandoz AG Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide
FR2919862A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 3-methylbutan-1-ol de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919867A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 2-methoxyethanol de rimonabant et son procede de preparation
FR2919864A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de 1,4-dioxane de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919863A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de n-methylpyrrolidone de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
FR2919865A1 (fr) * 2007-08-06 2009-02-13 Sanofi Aventis Sa Le solvate de dmso de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
WO2009153804A1 (en) * 2008-06-16 2009-12-23 Cadila Healthcare Limited Process for preparing form i of rimonabant
WO2010079241A1 (es) 2009-01-12 2010-07-15 Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
FR3008620A1 (fr) * 2013-07-22 2015-01-23 Sanofi Sa Formulation de comprime d'un inhibiteur de phosphatidylinositol 3-kinase
CN114555557A (zh) * 2019-10-16 2022-05-27 大塚制药株式会社 森塔纳法啶的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
AU2002331595A1 (en) * 2001-08-15 2003-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Novel vasoconstrictor cannabinoid analogs
FR2831883B1 (fr) * 2001-11-08 2004-07-23 Sanofi Synthelabo Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
IS7226A (is) 2004-04-19
AP1830A (en) 2008-02-22
KR20090089485A (ko) 2009-08-21
MEP21908A (en) 2010-06-10
CN1582278A (zh) 2005-02-16
JP2005508383A (ja) 2005-03-31
MXPA04004394A (es) 2004-08-11
HRP20040403A2 (en) 2004-08-31
HUP0402043A3 (en) 2009-07-28
TNSN04079A1 (fr) 2006-06-01
ECSP045088A (es) 2004-06-28
EA200400491A1 (ru) 2004-12-30
CN100412063C (zh) 2008-08-20
OA12721A (fr) 2006-06-27
GEP20063894B (en) 2006-08-10
EA006771B1 (ru) 2006-04-28
ZA200402999B (en) 2005-04-20
PL369372A1 (en) 2005-04-18
BR0213931A (pt) 2004-09-08
NZ532369A (en) 2005-10-28
TW200302824A (en) 2003-08-16
NO20041879D0 (no) 2004-05-07
IL161533A0 (en) 2004-09-27
US20050043356A1 (en) 2005-02-24
KR20050043774A (ko) 2005-05-11
NO20041879L (no) 2004-06-08
UA76776C2 (uk) 2006-09-15
NO326648B1 (no) 2009-01-26
JP4931874B2 (ja) 2012-05-16
CO5580827A2 (es) 2005-11-30
CA2464145A1 (en) 2003-05-15
HUP0402043A2 (hu) 2005-01-28
WO2003040105A1 (fr) 2003-05-15
RS36904A (en) 2006-10-27
JP2009035547A (ja) 2009-02-19
MA27080A1 (fr) 2004-12-20
CR7333A (es) 2008-09-23
EP1446384A1 (fr) 2004-08-18
AU2002350869B2 (en) 2007-07-26
FR2831883A1 (fr) 2003-05-09
IL161533A (en) 2010-05-31
US20100190827A1 (en) 2010-07-29
JP4181994B2 (ja) 2008-11-19
FR2831883B1 (fr) 2004-07-23
AP2004003024A0 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
AR037253A1 (es) Forma polimorfa de rimonabant, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
WO2005000820A3 (fr) Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1
ZA200408335B (en) Pyrrolidinium derivatives as antagonists of M3 muscarinic receptors.
DE60218340D1 (de) 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten
WO2002072570A3 (en) Non-imidazole compounds as histamine h3 antagonists
IL168056A0 (en) Selected cgrp antagonists, method for production and use thereof as medicament
PL376440A1 (en) Pyridopyrrolizine and pyridoindolizine derivatives
HK1082744A1 (en) Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
NO20034122D0 (no) Sammensmeltede pyridinderivater for anvendelse som vanilloidreseptorantagonister for behandling av smerte
DK1429761T3 (da) Hidtil ukendte 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning
EP1224173A4 (en) PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS
DE50011035D1 (de) Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
PL377215A1 (pl) Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego
HUP0402588A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them, process for producing them and their use
MY132566A (en) Benzimidazolone histamine h3 antagonists
IL173289A0 (en) Substituted thiazole-benzoisothiazole dioxide derivatives, method for the production thereof and use of the same
HUP0301671A3 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use
ATE541843T1 (de) 2-acylamino-4-phenylthiazolderivate, ihre herstellung und anwendung als chemokin antagonisten
ZA200409862B (en) Benzofused heteroaryl derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
PL377296A1 (pl) Pochodne 1,5-diarylo-pirolo-3-karboksyamidu oraz ich zastosowanie jako modulatorów receptora kannabinoidowego
ZA200502247B (en) Selected CGRP antagonists, method for production and use thereof as medicament.
IL158115A0 (en) Sapogenin derivatives, their synthesis and use, and methods based upon their use
AU2002352476A8 (en) Urea derivatives and their use as vanilloid receptor antagonists
ID30484A (id) Turunan 4-heterosikliksulfonamidil 6 metoksi 5 (2 metoksi fenoksi) 2 piridil-pirimidin, pembuatannya dan penggunaan sebagai antagonis reseptor endotelin
AU2003256793A1 (en) Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses

Legal Events

Date Code Title Description
FB Suspension of granting procedure